# Synergistic Cellular Toxicity from Inhibition of Poly(ADP-ribose) Glycohydrolase (PARG) and Ubiquitin-Specific Protease 1 (USP1)

**Authors:** Stefan M. Leonard, Charlotte R. Pearson, Wynand P. Roos, Robert W. Sobol

PMC · DOI: 10.3390/toxics14020162 · Toxics · 2026-02-10

## TL;DR

Combining inhibitors of USP1 and PARG causes increased cell toxicity by affecting DNA repair processes.

## Contribution

The study reveals a synergistic cytotoxic effect when inhibiting both USP1 and PARG, suggesting a novel therapeutic strategy.

## Key findings

- Inhibiting USP1 and PARG together increases mono-ubiquitinated PCNA levels and reduces PAR accumulation.
- The combination of ML323 and PDD00017273 shows synergistic cytotoxicity in cells.
- The relationship between USP1 and PARG inhibition suggests a potential synthetic lethal interaction.

## Abstract

Ubiquitin-specific protease 1 (USP1) is an emerging target for poly(ADP-ribose) polymerase 1 (PARP1) inhibitor-resistant and BRCA1/BRCA2 mutant tumors. USP1 is a deubiquitylating enzyme responsible for the removal of the mono-ubiquitin mark on FANCD2, PARP1, and the replication factor proliferating cell nuclear antigen (PCNA), among other proteins. USP1 facilitates proper PCNA-mediated polymerase switching from error-prone trans-lesion synthesis DNA polymerases to replicative DNA polymerases. Due to the critical role of USP1 in DNA synthesis and DNA repair, and the discovery that USP1 deubiquitylates PARP1, USP1 inhibitors (USP1i) were found to have a synthetic lethal relationship with PARP1 inhibitors (PARPi), suggesting a mechanistic link between poly(ADP-ribose) (PAR) dynamics and USP1-mediated ubiquitin hydrolysis. However, the relationship between USP1 inhibition and inhibitors of poly(ADP-ribose) glycohydrolase (PARGi), the primary enzyme responsible for PAR hydrolysis, has not been resolved. Using cell cytotoxicity, synergy, PCNA-ubiquitin, and PAR analyses, it is demonstrated herein that PARG inhibition, combined with USP1 inhibition, leads to increased levels of mono-ubiquitinated PCNA, decreased PAR accumulation, and synergistic cytotoxicity between ML323, a potent USP1i, and PDD00017273, a model PARGi. Future studies will focus on the mechanism that contributes to USP1/PARG synthetic lethality, the mechanism of cell death, and the impact of USP1 on PAR/ubiquitin dynamics and replication stress signaling.

## Linked entities

- **Genes:** USP1 (ubiquitin specific peptidase 1) [NCBI Gene 7398], PARP1 (poly(ADP-ribose) polymerase 1) [NCBI Gene 142], BRCA1 (BRCA1 DNA repair associated) [NCBI Gene 672], BRCA2 (BRCA2 DNA repair associated) [NCBI Gene 675], FANCD2 (FA complementation group D2) [NCBI Gene 2177], PCNA (proliferating cell nuclear antigen) [NCBI Gene 5111]
- **Proteins:** USP1 (ubiquitin specific peptidase 1), PARP1 (poly(ADP-ribose) polymerase 1), FANCD2 (FA complementation group D2), PCNA (proliferating cell nuclear antigen)
- **Chemicals:** ML323 (PubChem CID 60167849), PDD00017273 (PubChem CID 121398766)

## Full-text entities

- **Genes:** SAR1A (secretion associated Ras related GTPase 1A) [NCBI Gene 56681] {aka SAR1, SARA1, Sara, masra2}, PRMT1 (protein arginine methyltransferase 1) [NCBI Gene 3276] {aka ANM1, HCP1, HRMT1L2, IR1B4}, APEX1 (apurinic/apyrimidinic endodeoxyribonuclease 1) [NCBI Gene 328] {aka APE, APE1, APEN, APEX, APX, HAP1}, RNF146 (ring finger protein 146) [NCBI Gene 81847], KRAS (KRAS proto-oncogene, GTPase) [NCBI Gene 3845] {aka 'C-K-RAS, C-K-RAS, CFC2, K-RAS2A, K-RAS2B, K-RAS4A}, FANCI (FA complementation group I) [NCBI Gene 55215] {aka KIAA1794}, XRCC1 (X-ray repair cross complementing 1) [NCBI Gene 7515] {aka RCC, SCAR26}, CHEK1 (checkpoint kinase 1) [NCBI Gene 1111] {aka CHK1, OZEMA21}, UBE2K (ubiquitin conjugating enzyme E2 K) [NCBI Gene 3093] {aka E2-25K, HIP2, HYPG, LIG, UBC1}, PARP2 (poly(ADP-ribose) polymerase 2) [NCBI Gene 10038] {aka ADPRT2, ADPRTL2, ADPRTL3, ARTD2, PARP-2, pADPRT-2}, ATG14 (autophagy related 14) [NCBI Gene 22863] {aka ATG14L, BARKOR, KIAA0831}, POLB (DNA polymerase beta) [NCBI Gene 5423], UBP1 (upstream binding protein 1) [NCBI Gene 7342] {aka LBP-1B, LBP-1a, LBP1A, LBP1B, TFCP2L5}, BRCA1 (BRCA1 DNA repair associated) [NCBI Gene 672] {aka BRCAI, BRCC1, BROVCA1, FANCS, IRIS, PNCA4}, PCNA (proliferating cell nuclear antigen) [NCBI Gene 5111] {aka ATLD2}, APTX (aprataxin) [NCBI Gene 54840] {aka AOA, AOA1, AXA1, EAOH, EOAHA, FHA-HIT}, HELLS (helicase, lymphoid specific) [NCBI Gene 3070] {aka ICF4, LSH, Nbla10143, PASG, SALNR, SMARCA6}, LIG3 (DNA ligase 3) [NCBI Gene 3980] {aka LIG2, LIG3alpha, MTDPS20}, FANCD2 (FA complementation group D2) [NCBI Gene 2177] {aka FA-D2, FA4, FACD, FAD, FAD2, FANCD}, TRAF2 (TNF receptor associated factor 2) [NCBI Gene 7186] {aka MGC:45012, RNF117, TRAP, TRAP3}, RPA1 (replication protein A1) [NCBI Gene 6117] {aka HSSB, MST075, PFBMFT6, REPA1, RF-A, RP-A}, PARP1 (poly(ADP-ribose) polymerase 1) [NCBI Gene 142] {aka ADPRT, ADPRT 1, ADPRT1, ARTD1, PARP, PARP-1}, FEN1 (flap structure-specific endonuclease 1) [NCBI Gene 2237] {aka FEN-1, MF1, RAD2}, ATAD5 (ATPase family AAA domain containing 5) [NCBI Gene 79915] {aka C17orf41, ELG1, FRAG1}, WDR48 (WD repeat domain 48) [NCBI Gene 57599] {aka Bun62, P80, SPG60, UAF1}, JTB (jumping translocation breakpoint) [NCBI Gene 10899] {aka HJTB, HSPC222, PAR, hJT}, PARG (poly(ADP-ribose) glycohydrolase) [NCBI Gene 8505] {aka PARG99}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, ATR (ATR checkpoint kinase) [NCBI Gene 545] {aka FCTCS, FRP1, MEC1, SCKL, SCKL1}, FUS (FUS RNA binding protein) [NCBI Gene 2521] {aka ALS6, ETM4, FUS1, HNRNPP2, POMP75, TLS}, USP1 (ubiquitin specific peptidase 1) [NCBI Gene 7398] {aka UBP}, RAD18 (RAD18 E3 ubiquitin protein ligase) [NCBI Gene 56852] {aka RNF73}, PRMT5 (protein arginine methyltransferase 5) [NCBI Gene 10419] {aka HRMT1L5, HSL7, IBP72, JBP1, SKB1, SKB1Hs}, TRIM28 (tripartite motif containing 28) [NCBI Gene 10155] {aka KAP1, PPP1R157, RNF96, TF1B, TIF1B, TIF1beta}, TRIP13 (thyroid hormone receptor interactor 13) [NCBI Gene 9319] {aka 16E1BP, MVA3, OOMD9, OZEMA9}
- **Diseases:** Toxicity (MESH:D064420), tumorigenic (MESH:D002471), deficient (MESH:D007153), necrosis (MESH:D009336), Fanconi anemia (MESH:D005199), BER deficiency (MESH:D000072662), ovarian cancer (MESH:D010051), Cancer (MESH:D009369), injury to (MESH:D014947), osteosarcoma (MESH:D012516), glioma (MESH:D005910), pancreatic cancer (MESH:D010190), colorectal, non-small cell lung, breast, and gastric cancers (MESH:D002289), HR (MESH:C535296)
- **Chemicals:** amphotericin (MESH:D000666), Hoechst 33342 (MESH:C017807), acetone (MESH:D000096), DPBS (-), propidium iodide (MESH:D011419), sodium bicarbonate (MESH:D017693), penicillin (MESH:D010406), PAR (MESH:D011064), NAD+ (MESH:D009243), Tween-20 (MESH:D011136), glucose (MESH:D005947), diethyl ether (MESH:D004986), formaldehyde (MESH:D005557), DAPI (MESH:C007293), DMSO (MESH:D004121), McCoy's 5A medium (MESH:C113109), CO2 (MESH:D002245), L-glutamine (MESH:D005973), MNNG (MESH:D008769), hygromycin (MESH:C026273), Bis-Tris (MESH:C026272), streptomycin (MESH:D013307), methanol (MESH:D000432), phosphate (MESH:D010710), ADP-ribose (MESH:D000246), ethanol (MESH:D000431), TBS (MESH:D013725)
- **Species:** Homo sapiens (human, species) [taxon 9606], Saccharomyces cerevisiae (baker's yeast, species) [taxon 4932]
- **Mutations:** S11150H
- **Cell lines:** ES-2 — Homo sapiens (Human), Embryonic stem cell (CVCL_C769), LN428 — Homo sapiens (Human), Glioblastoma, Cancer cell line (CVCL_3959), U2OS — Homo sapiens (Human), Osteosarcoma, Cancer cell line (CVCL_0042)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12944873/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12944873/full.md

## References

111 references — full list in the complete paper: https://tomesphere.com/paper/PMC12944873/full.md

---
Source: https://tomesphere.com/paper/PMC12944873